Literature DB >> 26045292

Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype.

Jae-Sook Ahn1, Hyeoung-Joon Kim2, Yeo-Kyeoung Kim1, Sung-Hoon Jung1, Deok-Hwan Yang1, Je-Jung Lee1, Il-Kwon Lee3, Nan Young Kim3, Mark D Minden4, Chul Won Jung5, Jun-Ho Jang5, Hee Je Kim6, Joon Ho Moon7, Sang Kyun Sohn7, Jong-Ho Won8, Sung-Hyun Kim9, Namshin Kim10, Kenichi Yoshida11, Seishi Ogawa11, Dennis Dong Hwan Kim4.   

Abstract

Entities:  

Keywords:  TET2; acute myeloid leukemia; homozygous mutation; normal karyotype

Mesh：

Substances：

Year:  2015        PMID： 26045292      PMCID： PMC4800711          DOI： 10.3324/haematol.2015.126227

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

1.  Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

Authors:  Olivier Nibourel; Olivier Kosmider; Meyling Cheok; Nicolas Boissel; Aline Renneville; Nathalie Philippe; Hervé Dombret; François Dreyfus; Bruno Quesnel; Sandrine Geffroy; Samuel Quentin; Catherine Roche-Lestienne; Jean-Michel Cayuela; Christophe Roumier; Pierre Fenaux; William Vainchenker; Olivier A Bernard; Jean Soulier; Michaëla Fontenay; Claude Preudhomme
Journal:  Blood       Date:  2010-05-20       Impact factor: 22.113

2.  TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Klaus H Metzeler; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Heiko Becker; John Curfman; Kelsi B Holland; Sebastian Schwind; Susan P Whitman; Yue-Zhong Wu; William Blum; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  J Clin Oncol       Date:  2011-02-22       Impact factor: 44.544

3.  Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies.

Authors:  Zhe Li; Xiaoqiang Cai; Chen-Leng Cai; Jiapeng Wang; Wenyong Zhang; Bruce E Petersen; Feng-Chun Yang; Mingjiang Xu
Journal:  Blood       Date:  2011-07-29       Impact factor: 22.113

4.  TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.

Authors:  Wen-Chien Chou; Sheng-Chieh Chou; Chieh-Yu Liu; Chien-Yuan Chen; Hsin-An Hou; Yuan-Yeh Kuo; Ming-Cheng Lee; Bor-Sheng Ko; Jih-Luh Tang; Ming Yao; Woei Tsay; Shang-Ju Wu; Shang-Yi Huang; Szu-Chun Hsu; Yao-Chang Chen; Yi-Chang Chang; Yi-Yi Kuo; Kuan-Ting Kuo; Fen-Yu Lee; Ming-Chi Liu; Chia-Wen Liu; Mei-Hsuan Tseng; Chi-Fei Huang; Hwei-Fang Tien
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

5.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

6.  Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice.

Authors:  Myunggon Ko; Hozefa S Bandukwala; Jungeun An; Edward D Lamperti; Elizabeth C Thompson; Ryan Hastie; Angeliki Tsangaratou; Klaus Rajewsky; Sergei B Koralov; Anjana Rao
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-22       Impact factor: 11.205

7.  Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia.

Authors:  Yeo-Kyeoung Kim; Hee-Nam Kim; Se Ryeon Lee; Jae-Sook Ahn; Deok-Hwan Yang; Je-Jung Lee; Il-Kwon Lee; Myung-Geun Shin; Hyeoung-Joon Kim
Journal:  Korean J Hematol       Date:  2010-03-31

Review 8.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  Acquired mutations in TET2 are common in myelodysplastic syndromes.

Authors:  Saskia M C Langemeijer; Roland P Kuiper; Marieke Berends; Ruth Knops; Mariam G Aslanyan; Marion Massop; Ellen Stevens-Linders; Patricia van Hoogen; Ad Geurts van Kessel; Reinier A P Raymakers; Eveline J Kamping; Gregor E Verhoef; Estelle Verburgh; Anne Hagemeijer; Peter Vandenberghe; Theo de Witte; Bert A van der Reijden; Joop H Jansen
Journal:  Nat Genet       Date:  2009-05-31       Impact factor: 38.330

10.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.

Authors:  Maria E Figueroa; Omar Abdel-Wahab; Chao Lu; Patrick S Ward; Jay Patel; Alan Shih; Yushan Li; Neha Bhagwat; Aparna Vasanthakumar; Hugo F Fernandez; Martin S Tallman; Zhuoxin Sun; Kristy Wolniak; Justine K Peeters; Wei Liu; Sung E Choe; Valeria R Fantin; Elisabeth Paietta; Bob Löwenberg; Jonathan D Licht; Lucy A Godley; Ruud Delwel; Peter J M Valk; Craig B Thompson; Ross L Levine; Ari Melnick
Journal:  Cancer Cell       Date:  2010-12-09       Impact factor: 38.585
View more
  10 in total

1.  TET2 Mutation and High miR-22 Expression as Biomarkers to Predict Clinical Outcome in Myelodysplastic Syndrome Patients Treated with Hypomethylating Therapy.

Authors:  Jina Yun; Young Sok Ji; Geum Ha Jang; Sung Hee Lim; Se Hyung Kim; Chan Kyu Kim; Sang Byung Bae; Jong Ho Won; Seong Kyu Park
Journal:  Curr Issues Mol Biol       Date:  2021-08-05       Impact factor: 2.976

2.  Consequences of mutant TET2 on clonality and subclonal hierarchy.

Authors:  Cassandra M Hirsch; Aziz Nazha; Kassy Kneen; Mohamed E Abazeed; Manja Meggendorfer; Bartlomiej P Przychodzen; Niroshan Nadarajah; Vera Adema; Yasunobu Nagata; Abhinav Goyal; Hassan Awada; Mohammad Fahad Asad; Valeria Visconte; Yihong Guan; Mikkael A Sekeres; Ryszard Olinski; Babal Kant Jha; Thomas LaFramboise; Tomas Radivoyevitch; Torsten Haferlach; Jaroslaw P Maciejewski
Journal:  Leukemia       Date:  2018-05-24       Impact factor: 12.883

Review 3.  Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia.

Authors:  Habsah Aziz; Chow Y Ping; Hamidah Alias; Nurul-Syakima Ab Mutalib; Rahman Jamal
Journal:  Front Pharmacol       Date:  2017-12-07       Impact factor: 5.810

4.  Progression inference for somatic mutations in cancer.

Authors:  Leif E Peterson; Tatiana Kovyrshina
Journal:  Heliyon       Date:  2017-04-11

5.  Ten-eleven translocation-2 affects the fate of cells and has therapeutic potential in digestive tumors.

Authors:  Feng Wang; Jing Zhang; Jian Qi
Journal:  Chronic Dis Transl Med       Date:  2020-01-08

Review 6.  Role of TET dioxygenases in the regulation of both normal and pathological hematopoiesis.

Authors:  Kanak Joshi; Lei Zhang; Peter Breslin S J; Ameet R Kini; Jiwang Zhang
Journal:  J Exp Clin Cancer Res       Date:  2022-10-07

7.  5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.

Authors:  Jae-Sook Ahn; Hyeoung-Joon Kim; Yeo-Kyeoung Kim; Seung-Shin Lee; Seo-Yeon Ahn; Sung-Hoon Jung; Deok-Hwan Yang; Je-Jung Lee; Hee Jeong Park; Seung Hyun Choi; Chul Won Jung; Jun-Ho Jang; Hee Je Kim; Joon Ho Moon; Sang Kyun Sohn; Jong-Ho Won; Sung-Hyun Kim; Szardenings Michael; Mark D Minden; Dennis Dong Hwan Kim
Journal:  Oncotarget       Date:  2017-01-31

8.  Acidic leucine-rich nuclear phosphoprotein-32A expression contributes to adverse outcome in acute myeloid leukemia.

Authors:  Sai Huang; Zhi Huang; Chao Ma; Lan Luo; Yan-Fen Li; Yong-Li Wu; Yuan Ren; Cong Feng
Journal:  Ann Transl Med       Date:  2020-03

Review 9.  Landscape of Tumor Suppressor Mutations in Acute Myeloid Leukemia.

Authors:  Cristina Panuzzo; Elisabetta Signorino; Chiara Calabrese; Muhammad Shahzad Ali; Jessica Petiti; Enrico Bracco; Daniela Cilloni
Journal:  J Clin Med       Date:  2020-03-16       Impact factor: 4.241

Review 10.  Role of Tet2 in Regulating Adaptive and Innate Immunity.

Authors:  Jiaqi Li; Lifang Li; Xiaoxiao Sun; Tuo Deng; Gan Huang; Xia Li; Zhiguo Xie; Zhiguang Zhou
Journal:  Front Cell Dev Biol       Date:  2021-06-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.